OCUL
Price
$7.30
Change
+$0.08 (+1.11%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
1.15B
79 days until earnings call
VRDN
Price
$13.56
Change
-$0.11 (-0.80%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
1.12B
74 days until earnings call
Interact to see
Advertisement

OCUL vs VRDN

Header iconOCUL vs VRDN Comparison
Open Charts OCUL vs VRDNBanner chart's image
Ocular Therapeutix
Price$7.30
Change+$0.08 (+1.11%)
Volume$39.31K
Capitalization1.15B
Viridian Therapeutics
Price$13.56
Change-$0.11 (-0.80%)
Volume$13.96K
Capitalization1.12B
OCUL vs VRDN Comparison Chart
Loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCUL vs. VRDN commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a Hold and VRDN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (OCUL: $7.22 vs. VRDN: $13.67)
Brand notoriety: OCUL and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCUL: 62% vs. VRDN: 61%
Market capitalization -- OCUL: $1.15B vs. VRDN: $1.12B
OCUL [@Biotechnology] is valued at $1.15B. VRDN’s [@Biotechnology] market capitalization is $1.12B. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCUL’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • OCUL’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, OCUL is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCUL’s TA Score shows that 2 TA indicator(s) are bullish while VRDN’s TA Score has 5 bullish TA indicator(s).

  • OCUL’s TA Score: 2 bullish, 8 bearish.
  • VRDN’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, VRDN is a better buy in the short-term than OCUL.

Price Growth

OCUL (@Biotechnology) experienced а +0.63% price change this week, while VRDN (@Biotechnology) price change was +8.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was +3.15%, and the average quarterly price growth was -3.91%.

Reported Earning Dates

OCUL is expected to report earnings on Aug 11, 2025.

VRDN is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($1.15B) and VRDN($1.12B) have the same market capitalization . OCUL YTD gains are higher at: -15.515 vs. VRDN (-28.691). OCUL has higher annual earnings (EBITDA): -176.35M vs. VRDN (-304.76M). VRDN has more cash in the bank: 637M vs. OCUL (350M). VRDN has less debt than OCUL: VRDN (21.2M) vs OCUL (76.2M). OCUL has higher revenues than VRDN: OCUL (59.6M) vs VRDN (302K).
OCULVRDNOCUL / VRDN
Capitalization1.15B1.12B103%
EBITDA-176.35M-304.76M58%
Gain YTD-15.515-28.69154%
P/E RatioN/AN/A-
Revenue59.6M302K19,735%
Total Cash350M637M55%
Total Debt76.2M21.2M359%
FUNDAMENTALS RATINGS
OCUL vs VRDN: Fundamental Ratings
OCUL
VRDN
OUTLOOK RATING
1..100
88
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
9084
SMR RATING
1..100
9494
PRICE GROWTH RATING
1..100
5861
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (50) in the Pharmaceuticals Other industry is somewhat better than the same rating for VRDN (92) in the Biotechnology industry. This means that OCUL’s stock grew somewhat faster than VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (84) in the Biotechnology industry is in the same range as OCUL (90) in the Pharmaceuticals Other industry. This means that VRDN’s stock grew similarly to OCUL’s over the last 12 months.

VRDN's SMR Rating (94) in the Biotechnology industry is in the same range as OCUL (94) in the Pharmaceuticals Other industry. This means that VRDN’s stock grew similarly to OCUL’s over the last 12 months.

OCUL's Price Growth Rating (58) in the Pharmaceuticals Other industry is in the same range as VRDN (61) in the Biotechnology industry. This means that OCUL’s stock grew similarly to VRDN’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as VRDN (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OCULVRDN
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 8 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCIRX15.43N/A
N/A
Goldman Sachs Intl Eq Insghts R
VAFAX28.26N/A
N/A
Invesco American Franchise A
ARYYX12.97N/A
N/A
American Century Global Real Estate Y
DBOCX23.21N/A
N/A
BNY Mellon Balanced Opportunity C
GCFSX17.22N/A
N/A
Gabelli Global Financial Services C

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-1.16%
EYPT - OCUL
59%
Loosely correlated
-4.60%
XENE - OCUL
49%
Loosely correlated
+0.10%
DNLI - OCUL
49%
Loosely correlated
-0.22%
NRIX - OCUL
49%
Loosely correlated
+2.15%
BEAM - OCUL
49%
Loosely correlated
N/A
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with DSGN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then DSGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+0.07%
DSGN - VRDN
49%
Loosely correlated
+7.50%
DNLI - VRDN
49%
Loosely correlated
-0.22%
OCUL - VRDN
47%
Loosely correlated
-1.16%
CCCC - VRDN
47%
Loosely correlated
N/A
AURA - VRDN
46%
Loosely correlated
N/A
More